Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes cedex, France.
University of Rennes 1, 35033, Rennes, France.
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):392-401. doi: 10.1007/s00259-017-3845-7. Epub 2017 Nov 25.
This study aimed at identifying prior therapy dosimetric parameters using Tc-labeled macro-aggregates of albumin (MAA) that are associated with contralateral hepatic hypertrophy occurring after unilobar radioembolization of hepatocellular carcinoma (HCC) performed with Y-loaded glass microspheres.
The dosimetry data of 73 HCC patients were collected prior to the treatment with Y-loaded microspheres for unilateral disease. The injected liver dose (ILD), the tumor dose (TD) and healthy injected liver dose (HILD) were calculated based on MAA quantification. Following treatment, the maximal hypertrophy (MHT) of an untreated lobe was calculated.
Mean MHT was 35.4 ± 40.4%. When using continuous variables, the MHT was not correlated with any tested variable, i.e., injected activity, ILD, HILD or TD except with a percentage of future remnant liver (FRL) following the Y-microspheres injection (r = -0.56). MHT ≥ 10% was significantly more frequent for patients with HILD ≥ 88 Gy, (52% of the cases), i.e., in 92.2% versus 65.7% for HILD < 88 Gy (p = 0.032). MHT ≥ 10% was also significantly more frequent for patients with a TD ≥ 205 Gy and a tumor volume (VT) ≥ 100 cm in patients with initial FRL < 50%. MHT ≥10% was seen in 83.9% for patients with either an HILD ≥ 88 Gy or a TD ≥ 205 Gy for tumors larger than 100cm (85% of the cases), versus only 54.5% (p = 0.0265) for patients with none of those parameters. MHT ≥10% was also associated with FRL and the Child-Pugh score. Using multivariate analysis, the Child-Pugh score (p < 0.0001), FRL (p = 0.0023) and HILD (p = 0.0029) were still significantly associated with MHT ≥10%.
This study demonstrates for the first time that HILD is significantly associated with liver hypertrophy. There is also an impact of high tumor doses in large lesions in one subgroup of patients. Larger prospective studies evaluating the MAA dosimetric parameters have to be conducted to confirm these promising results.
本研究旨在通过使用 Tc 标记的白蛋白微球(MAA)确定与单侧肝动脉化疗栓塞(TACE)治疗后发生的对侧肝肥大相关的治疗前剂量学参数。
收集 73 例 HCC 患者在接受 Y 载玻璃微球单侧疾病治疗前的剂量学数据。根据 MAA 定量计算注射肝剂量(ILD)、肿瘤剂量(TD)和健康注射肝剂量(HILD)。治疗后,计算未治疗叶的最大肥大(MHT)。
平均 MHT 为 35.4±40.4%。当使用连续变量时,MHT 与任何测试变量均无相关性,即注入活性、ILD、HILD 或 TD,除了 Y 微球注射后剩余肝的百分比(FRL)外(r=-0.56)。当 HILD≥88Gy 时(病例中的 52%),MHT≥10%的情况明显更为常见,即 HILD<88Gy 时(65.7%)为 92.2%(p=0.032)。当 TD≥205Gy 且初始 FRL<50%时肿瘤体积(VT)≥100cm时,MHT≥10%的情况也明显更为常见。对于 FRL≥88Gy 或 TD≥205Gy 的患者,肿瘤大于 100cm 时,MHT≥10%的比例为 83.9%(85%的病例),而对于无上述参数的患者,该比例仅为 54.5%(p=0.0265)。MHT≥10%也与 FRL 和 Child-Pugh 评分相关。多变量分析显示,Child-Pugh 评分(p<0.0001)、FRL(p=0.0023)和 HILD(p=0.0029)与 MHT≥10%仍显著相关。
本研究首次证明 HILD 与肝肥大显著相关。在一个亚组患者中,大病灶高肿瘤剂量也有影响。需要进行更大规模的前瞻性研究来评估 MAA 剂量学参数,以证实这些有前景的结果。